Screening for Fabry Disease in Patients with Left Ventricular Hypertrophy in China: A Multicentre and Prospective Study
ESC Heart Failure · 2024
DOI: 10.1002/ehf2.15065 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift ESC Heart Failure, 2024. Verfasst von Zongwei Lin und 13 weiteren Autor:innen. Beteiligte Einrichtung: National Key Laboratory for Innovation and Transformation of Luobing Theory, Key Laboratory of Cardiovascular Remodeling and Function Research, Chine…. Hauptthemen laut MEDLINE: Fabry Disease, Hypertrophy, Left Ventricular, Echocardiography. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Clinical Research Center of Shandong University.
Abstract (Originalsprache)
Aims
Left ventricular hypertrophy (LVH) is frequently detected via echocardiography in individuals with Fabry disease (FD), sometimes leading to confusion with hypertrophic cardiomyopathy (HCM) of other aetiologies. Considering this diagnosis challenge, FD should be included in the list of differential diagnosis for patients presenting with LVH. To address this concern, we conducted a prospective screening study in China, using dried blood spot (DBS) testing, to evaluate patients with unexplained LVH.
Methods
Our study was designed as a nationwide, multicentre prospective investigation. A total of 1015 patients from 55 different centres who were diagnosed with LVH by echocardiography were screened in the study from September 2022 to December 2023. Demographic information, biochemistry data, echocardiography parameters and clinical observations were meticulously collected from all participants. The DBS method was used to assess α-galactosidase A (α-Gal A) activity in males and both α-Gal A and globotriaosylsphingosine (lyso-Gb3) levels in females.
Results
The final screening population included 906 patients (589 males, 65%) with LVH, characterized by a mean maximal myocardial thickness of 14.8 ± 4.6 mm and an average age of 56.9 ± 17.2 years. In total, 43 patients (38 males, 5 females) exhibited low α-Gal A activity measurement (<2.2 μmol/L), while 21 patients (10 males, 11 females) presented low α-Gal A activity or elevated lyso-Gb3 levels (>1.1 ng/mL). Among these patients, eight individuals (7 males and 1 female) were genetically confirmed to harbour pathogenic GLA mutations, resulting in a total prevalence of 0.88%. Compared with patients without FD, patients with FD tended to have proteinuria (75% vs. 21.2%, P = 0.001), family history of HCM (37.5% vs. 2.3%, P < 0.01) and neuropathic pain (37.5% vs. 4.4%, P < 0.01) but lower systolic blood pressure (118.5 ± 12.5 vs. 143.3 ± 29.3 mmHg, P = 0.017). Five mutations were previously recognized as associated with FD while the remaining two, p.Asp313Val (c.938A>T) and c.547+3A>G, were deemed potentially pathogenic. Subsequent familial validation post-diagnosis identified an additional 14 confirmed cases.
Conclusions
This pioneering screening study for FD among Chinese patients with unexplained LVH using DBS measurement, revealed an FD detection rate of 0.88%. Our findings confirmed that the combined measurement of lyso-Gb3 and α-Gal A activity is beneficial for primary screening of FD in patients with LVH. Given the availability of efficacious therapies and the value of cascade screening in extended families, early detection of FD in LVH patients is clinically important.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Key Laboratory for Innovation and Transformation of Luobing Theory, Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chine…
- Department of Cardiology, Dongying People's Hospital, Dongying, China.
- Department of Cardiology, Tai'an Central Hospital, Tai'an, China.
- Department of Cardiology, People's Hospital of Ningjin County Shandong Province, Dezhou, China.
- Department of Cardiology, Xintai Hospital of Chinese Traditional Medicine, Tai'an, China.
- Department of Cardiology, Qingdao Municipal Hospital, Qingdao, China.
ORCID-Profile: Huixia Lu
Förderung
- Clinical Research Center of Shandong University
Zitieren
APA
Lin, Z., Zhang, X., Liu, Y., Miao, D., Zhang, H., Zhang, T., Zhang, F., Li, P., Dai, H., Jiang, G., Zhang, D., Zhong, L., Lu, H., & Ji, X. (2024). Screening for Fabry Disease in Patients with Left Ventricular Hypertrophy in China: A Multicentre and Prospective Study. ESC Heart Failure. https://doi.org/10.1002/ehf2.15065
Vancouver
Lin Z, Zhang X, Liu Y, Miao D, Zhang H, Zhang T, et al. Screening for Fabry Disease in Patients with Left Ventricular Hypertrophy in China: A Multicentre and Prospective Study. ESC Heart Failure. 2024. doi:10.1002/ehf2.15065
BibTeX
@article{Lin2024,
author = {Lin, Zongwei and Zhang, Xinyu and Liu, Yan and Miao, Dongxia and Zhang, Huanyi and Zhang, Tao and Zhang, Fenglei and Li, Peng and Dai, Hongyan and Jiang, Guihua and Zhang, Dongxia and Zhong, Lin and Lu, Huixia and Ji, Xiaoping},
title = {Screening for Fabry Disease in Patients with Left Ventricular Hypertrophy in China: A Multicentre and Prospective Study},
journal = {ESC Heart Failure},
year = {2024},
doi = {10.1002/ehf2.15065}
}
EUVIMED